A retrospective Canadian study reported real-world outcomes for mavacamten in patients with obstructive hypertrophic cardiomyopathy treated outside tightly controlled trial settings. The analysis of 115 patients found improvements in symptoms and outflow tract obstruction, with modest ejection fraction declines and no cases dropping below 30%, supporting continued use while monitoring for safety signals.